JP2022007769A - Composition for inhibiting phosphodiesterase 5 activity or improving erectile function - Google Patents

Abstract

To provide a new application of a processed product of a Phyllanthus plant.SOLUTION: The present invention discloses a composition for inhibiting phosphodiesterase 5 activity, a composition for improving the erectile function, and a composition for improving at least one selected from the group consisting of prostatic hyperplasia, the urination function, the urine storage function, and the male vigor, containing a processed product of a Phyllanthus plant as an active ingredient.SELECTED DRAWING: None

Description

The present invention relates to new uses for processed products of plants of the genus Phyllanthus.

Amla is a plant belonging to the genus Phyllanthaceae, also known as gooseberry (scientific name: Phyllanthus emblica), and is rich in polyphenols such as Elaeocarpusin, Chebulagicacid, and Geraniin. It is known to be included (Patent Document 1).

Conventionally, Amla has an effect of improving blood flow, an effect of inhibiting fibrin formation, and an effect of suppressing platelet aggregation (Patent Document 2-4), and also has an effect of improving stiff shoulders, an antithrombotic effect, an effect of improving swelling, and prevention of economy class syndrome. It is also known to be effective (Patent Document 5-8).
Elagitannin contained in Amla is an ester of glucose and ellagic acid, and when hydrolyzed, ellagic acid is produced (Non-Patent Document 1). It has been reported that ellagic acid has a high antioxidant effect, an anticancer effect, and an effect of improving hepatic steatosis due to a resistin secretion inhibitory effect (Non-Patent Document 2-4).

However, none of these prior literatures describe that amla and its components have an action of inhibiting phosphodiesterase activity or an action of improving erectile function.

Japanese Unexamined Patent Publication No. 2006-335736 Japanese Unexamined Patent Publication No. 2006-335708 Japanese Unexamined Patent Publication No. 2006-8259 Japanese Unexamined Patent Publication No. 2006-137071 Japanese Unexamined Patent Publication No. 2006-335721 Japanese Unexamined Patent Publication No. 2005-162648 Japanese Unexamined Patent Publication No. 2006-335711 Japanese Unexamined Patent Publication No. 2006-335710

Lei F., Xi ng DM., Xiang L., Zhao YN., Wang W (2003) Pharmakokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract. J Chromatogr B 796: 189-194. Hassoun, E. A., Walter, A. C., Alshar if, N. Z., & Stohs, S. J. Modulation of TCDD induced fetotoxicity and oxidative stress in embryonic and placental tissues of C57BL / 6J mice by vitamin E succinate and ellagic acid. Toxicology 124 1: 27 37. A. Nar ayanan, Bhagavathi & Geoffroy, Otto & C. Willingham, Mark & G. Re, Gian & W. Nixon, Daniel (1999) P53 / p21 (WAF1 / CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Letters 136: 215 221. Yoshimura Y., Nishii S., Zaima N., Moriyama T., Kaw amura Y. (2013) Ellagic acid improves hepatic steatosis and serum lipid composition through reduction of serum resistin levels and transcriptional activation of hepatic ppara in obese, diabetic KK Ay mice. Biochem Biophys Res Commun 434: 486 491. Prapapan T., Thomas RH, Joseph AB, Jarupa V., Khanit S., Wittaya P., Pattara S., Kornkanok I. (2013) Kaempferia Parviflora, a Plant Used in Traditional Medicine to Enhance Sexual Performance Contains Large Amounts of Low Affinity PDE5 Inhibitors. J Ethnopharmacol, 2011 Oct 11; 137 (3): 1437-41.

An object of the present invention is to provide a new use of a processed product of a plant belonging to the genus Phyllanthus. Specifically, the present invention provides a composition that inhibits the activity of phosphodiesterase 5 (hereinafter referred to as "PDE5") containing a processed product of a plant of the genus Phyllanthus as an active ingredient, or a composition that improves erectile function in men. That is the issue. Further, it is an object of the present invention to provide a composition containing the processed plant product as an active ingredient to improve benign prostatic hyperplasia, urination function, urination function, and male vitality.

As a result of diligent studies to solve the above problems, the present inventors have found that processed products of Phyllanthus genus plants, particularly extracts extracted from Amla fruits, have excellent PDE5 activity inhibitory action and erectile function improving action. In other words, it has been found to have the effect of improving and improving the vitality of men. The present invention has been completed with further studies based on these findings, and includes the following embodiments.

1. 1. A composition for inhibiting PDE5 activity containing a processed product of a plant belonging to the genus Phyllanthus as an active ingredient.
2. 2. A composition for improving erectile function containing a processed product of a plant of the genus Phyllanthus as an active ingredient.
3. 3. At least one composition for improvement selected from the group consisting of benign prostatic hyperplasia symptoms, urinary function, livestock urinary function, and male vitality containing a processed product of a plant of the genus Phyllanthus as an active ingredient.
4. Item 6. The composition according to any one of Items 1 to 3, wherein the plant of the genus Phyllanthus is Amla.
5. Item 6. The composition according to any one of Items 1 to 4, wherein the composition is a food or drink composition, a pharmaceutical composition or a feed composition.

According to the composition of the present invention, the activity of PDE5 can be inhibited. Therefore, the composition of the present invention maintains and enhances the health and vitality of men, in particular, for the purpose of improving or improving conditions caused by decreased blood flow, such as penile erection function, lower urinary tract dysfunction, and benign prostatic hyperplasia. Can be used for the purpose.

In Experimental Example 2, the result of evaluating the erection-inducing effect of Amla extract by measuring the penis length using a rabbit is shown. In the figure, "SNP" means nitric oxide (NO) donor sodium nitroprusside (same for the following figures). (A) shows the change in penis length (mm) before intravenous administration of SNP (0 min) and 30 minutes (30 min) after intravenous administration of Amla extract after continuous oral administration. (B) is a figure comparing the penis length (mm) at the time point of 30 minutes after SNP administration for four test groups by a bar graph. In Experimental Example 2, the images of the penis of rabbits in the SNP 1 mg / kg + Amla extract 500 mg / kg administration group, which showed particularly remarkable effects, before SNP administration (left figure) and 30 minutes after SNP administration (right figure). be. In Experimental Example 3, the results of evaluating the erection-inducing effects of sildenafil, walnut extract, mozuku extract, and amla extract by measuring the penis length using rabbits are shown. The changes in penis length (mm) between before intravenous administration of SNP (0 min) and 30 to 120 minutes (30 to 120 min) after continuous oral administration of each sample are shown.

The present invention provides a composition for inhibiting PDE5 activity, which comprises a processed product of a plant belonging to the genus Phyllanthus as an active ingredient. The present invention also provides a composition for improving erectile function containing the processed product as an active ingredient.

The leaves of the genus Phyllanthaceae are plants belonging to the family Phyllanthaceae, and among them, Amla (Phyllanthus emblica) has been conventionally useful for improving blood flow, inhibiting fibrin formation, suppressing platelet aggregation and the like, as described above. It is a plant known to have various pharmacological actions.

The various compositions of the present invention can be prepared from the processed products of the leaves of the genus Phyllanthus as raw materials. The site of the plant of the genus Phyllanthus used as a raw material is not particularly limited as long as the effect of the present invention is exhibited, and leaves, stems, fruits, flowers, buds, branches, trunks, bark, roots, flower buds, seeds, seed coats. Etc. can be selected. Fruits, bark, roots and leaves are preferable, and fruits are more preferable.

In the present invention, the processed products of Phyllanthus genus include crushed products, juices, dried products, extracts and the like of the plant parts.

The crushed product may be any crushed product of the plant part, and the preparation method thereof and the crushed state thereof are not particularly limited. For example, a method of crushing with a crusher known in the art such as a jet mill can be exemplified. In addition, the juice can be prepared according to a conventional method.

The dried product may be any product obtained by drying the plant part, and the preparation method thereof and the dried state thereof are not particularly limited. For example, conventionally known drying methods such as sun drying, far infrared irradiation, and a dryer (hot air drying, cold air drying, vacuum freezing drying, etc.) can be exemplified. Although the amount of water in the dried product is not limited, it can be preferably about 10% by weight or less, more preferably about 8% by weight or less. In the present invention, the form of the dried product is not limited, and any of the dried product of the plant part itself, the crushed product of the dried product, and the like may be used. The dried pulverized product can be obtained by pulverizing the dried product according to the same method as the pulverized product. The above-mentioned juice can also be prepared as a dried juice by squeezing the juice and then drying it.

The extract may be any one obtained by extracting the components from the plant site using a solvent described later, and the preparation method (extraction method, extraction conditions, etc.) thereof is not particularly limited. For example, the plant part can be cut, crushed, dried or the like as it is, if necessary, and then extracted with a solvent to obtain an extract. As the solvent extraction method, a method known in the art may be adopted, and conventionally known extraction methods such as water (including hot water and hot water) extraction, alcohol extraction, supercritical extraction and the like can be used. ..

When solvent extraction is performed, the solvent may be, for example, water; lower alcohols such as methanol, ethanol and isopropanol, and alcohols such as polyhydric alcohols such as propylene glycol and 1,3-butylene glycol (whether anhydrous or water-containing). ); Ketones such as acetone, esters such as diethyl ether, dioxane, acetonitrile and ethyl acetate, xylene, benzene, chloroform and the like. The solvent is preferably water, a lower alcohol, 1,3-butylene glycol or the like, more preferably water, methanol, ethanol or 1,3-butylene glycol, and further preferably water, methanol or hydrous ethanol. These solvents may be used alone or in combination of two or more.

In the present invention, the extract thus obtained through solvent extraction can be particularly referred to as a solvent extract. Further, although not limiting the present invention, for example, when water is used as a solvent, it is referred to as a water extract, when alcohols are used, it is referred to as an alcohol extract, and when a hydrous alcohol is used, it is referred to as a hydrous alcohol extract. be able to.

The obtained extract may be used as it is, or may be dried and used in a solid state such as powder or granules. Further, if necessary, the obtained extract may be subjected to purification, concentration treatment, separation treatment of highly active fractions and the like. Although not limiting the present invention, examples of the purification treatment include treatments such as filtration, adsorption using an ion exchange resin, an activated carbon column, and decolorization. Further, as the concentration treatment, a conventional method such as an evaporator can be used. Further, as the separation treatment of the highly active fraction, known separation treatments such as gel filtration, adsorption treatment, silica gel column chromatography, and HPLC (High performance liquid chromatography) can be used.

Further, for example, a method for pulverizing the extract obtained as described above (further, its dried product, purified product, concentrated product, highly active fraction) by freeze-drying treatment, if necessary. The extract may be used in the present invention by adding excipients such as dextrin, cornstarch, and gum arabic and pulverizing according to a conventionally known method such as a method of pulverizing by spray-drying. Further, the extract may be further dissolved in an edible solvent such as water or ethanol, if necessary, and used.

In the present invention, the processed product of a plant belonging to the genus Phyllanthus is preferably an extract (including a concentrate and / or a dried product thereof). The extract is particularly preferably an extract obtained by drying, crushing and / or cutting the site of use of the leafflower genus plant as a raw material, extracting and filtering using a suitable solvent, and in this way. It is an extract obtained by further drying the obtained extract. Although not limiting the present invention, the extract may be used, for example, in 100 g of a used site (preferably fruit) of a plant of the genus Phyllanthus as a raw material, preferably a dried product, a crushed product and / or a cut product of the used site. On the other hand, using 1 to 50 liters of extraction solvent, leach-extraction was performed at an arbitrary temperature (for example, 15 to 90 ° C.) for an arbitrary time (for example, 10 minutes to 24 hours) with stirring as needed. It can then be obtained by filtering.

The processed product of the plant of the genus Phyllanthus used in the present invention may be a commercially available product, or may be a commercially available product that has been further subjected to a treatment such as drying.

The content of the processed product of the plant of the genus Phyllanthus in the composition of the present invention is not limited as long as the processed product is contained in the composition and the effect of the present invention can be obtained. For example, in the present composition, the processed product can be selected from the range of more than 0% by weight and 100% by weight or less, preferably 0.001 to 99% by weight in terms of dry matter.

Further, in the composition of the present invention, the dose (ingestion) of the processed product of the plant of the genus Phyllanthus is not particularly limited as long as the effect of the present invention is exhibited, and the physique, age and symptoms of the subject (target animal). , Appropriately set according to the application form, the degree of expected effect, and the like. The subject (target animal) of the present composition is a male adult (adult), a male (male) 18 years or older, preferably 40 years or older in terms of human age. The daily dose (intake) is not limited, but is preferably 0.5 to 10000 mg, more preferably 5 to 4000 mg in terms of dry weight of the processed plant product, based on an adult having a body weight of 60 kg. The composition of the present invention may be a single dose (ingestion) or a plurality of doses (ingestion) per day.

The composition of the present invention can be prepared in a form of oral administration or parenteral administration, but preferably has an oral administration form. The specific form is not particularly limited, and may be appropriately set according to the purpose. Liquid forms of the composition of the present invention include liquids, emulsions, suspensions, syrups, extracts, liquor, elixirs, etc .; powders, granules, fine granules, tablets, pills, capsules ( Solid forms such as hard capsules and soft capsules), troches, chewables, etc .; In addition, various forms such as gel-like, cream-like, paste-like, mousse-like semi-solid forms are exemplified.

For example, when the composition of the present invention is in a solid form, it may be mixed with water or the like at the time of use. Further, the composition of the present invention may be a sustained release dosage form. Further, for example, the tablet may be a conventionally known coated tablet, for example, a sugar-coated tablet, a gelatin-encapsulated tablet, an enteric-coated tablet, a film-coated tablet, a double tablet, or a multi-layer tablet, if necessary. ..

Further, the mode of use of the composition of the present invention is not limited, and may be appropriately set according to the intended purpose. As a mode of use of the composition of the present invention, food compositions (including beverages, health functional foods (including specified health foods, nutritional functional foods, foods with functional claims, supplements, etc.), foods for the sick, etc.), It can be used as a pharmaceutical composition, a feed composition, an additive to a food composition, a pharmaceutical composition, a feed, or the like.

The composition of the present invention may be produced according to conventionally known conventional procedures in the above-mentioned various forms, usage modes, etc., and if necessary, components permitted for the production of foods, components pharmaceutically acceptable. , It may be manufactured by mixing with an arbitrary component such as an edible component. As the optional component, a solvent (water, lower alcohol such as methanol, ethanol, isopropanol, alcohols such as propylene glycol, polyhydric alcohol such as 1,3-butylene glycol (whether anhydrous or water-containing), etc.) and the like). , Excipients, disintegrants, diluents, lubricants, fragrances, colorants, sweeteners, flavoring agents, suspending agents, wetting agents, emulsifiers, solubilizers, dispersants, buffers, binders, penetration promoting Agents, stabilizers, bulking agents, preservatives, thickeners, pH regulators, surfactants, coating agents, absorption promoters, adsorbents, fillers, antioxidants, refreshing agents, film forming agents, gelling agents , Amino acids, vitamins, enzymes, various nutritional components and the like are exemplified. These may be used alone or in combination of two or more.

In the present invention, the subject (target animal) of the present composition is as described above, and the target animal includes animals such as mice, rats, guinea pigs, rabbits, dogs, cats, monkeys, pigs, cows, and horses. Animals such as mice, rats, guinea pigs, rabbits, dogs and monkeys are preferably exemplified.

According to the composition of the present invention, as shown in Experimental Example 1 described later, the phosphodiesterase 5 (PDE5) activity can be inhibited based on the action of the processed product of the plant of the genus Phyllanthus. From this, the present invention provides a composition for inhibiting PDE5 activity containing the processed product of the plant as an active ingredient, and also comprises a step of preparing the processed product of the plant. It provides a manufacturing method of. It can also be said that the present invention provides a method for inhibiting PDE5 activity, which is characterized by using the processed product of the plant. Furthermore, the present invention provides a method for imparting a PDE5 activity inhibitory effect to a food composition, a pharmaceutical composition, or a feed composition by blending the processed plant product with the food composition, the pharmaceutical composition, or the feed composition. You can also.

According to the composition of the present invention, as shown in Experimental Examples 2 and 3 described later, it is possible to induce an erection based on the action of the processed product of the leafflower genus plant and to enhance the sustainability of the erection. From this, the present invention provides a composition for improving erectile function containing the processed product of the plant as an active ingredient, and the composition for improving erectile function including a step of preparing the processed product of the plant. It provides a manufacturing method of. It can also be said that the present invention provides a method for improving erection function (for example, a method for inducing erection and / or improving sustainability of erection), which is characterized by using the processed product of the plant. Further, according to the present invention, by blending the processed plant product into a food composition, a pharmaceutical composition, or a feed composition, an erection function improving action (for example, an erection-inducing action and / or an erection) is added to these compositions. It can also be said to provide a method of imparting a sustainability improving effect). As described above, the composition of the present invention can be suitably used for improving and improving the vitality of men by improving energy loss, erectile dysfunction, premature ejaculation and the like.

PDE5 is an enzyme mainly involved in the degradation of cGMP. cGMP acts as an intracellular second messenger, relaxing smooth muscle and increasing blood flow. Therefore, by inhibiting the activity of PDE5, smooth muscle relaxes and blood flow increases. As a drug utilizing this action, a PDE5 inhibitor is known today, and a typical drug such as a drug containing sildenafil citrate as an active ingredient is known. PDE5 inhibitors have been used for the purpose of improving symptoms such as decreased penile erection ability, decreased bladder and prostate function, and pulmonary hypertension by increasing local blood flow based on the above-mentioned effects. Therefore, it is considered that the composition of the present invention can also improve the penile erectile function by relaxing the smooth muscle due to the PDE5 inhibitory action and thereby increasing the blood flow to the corpus cavernosum penis. Similarly, the PDE5 inhibitory effect can improve lower urinary tract disorders (for example, improvement of urinary function and urinary storage function) by increasing blood flow to the urinary system, and increase blood flow in the prostate and urethra. It is thought that this can alleviate the enlargement of the prostate. Furthermore, due to the PDE5 inhibitory action, it is possible to reduce the pulmonary arterial pressure by increasing the blood flow to the lung tissue.

From this, the composition of the present invention can also be preferably applied to a subject who is concerned about male function (a subject who wants to improve and improve male vitality), a subject who is concerned about urination function, and the like. .. As described above, the composition of the present invention is a composition for inhibiting PDE5 activity, a composition for improving penile erection function (deficiency), a composition for improving lower urinary tract function, a composition for improving benign prostatic hyperplasia, and a composition for improving pulmonary hypertension. It can also be suitably used as a composition (particularly pulmonary arterial hypertension) and the like.

As described above, in the present specification, the terms "contains" and "contains" include the meanings of "consisting of" and "substantially consisting of".

Hereinafter, the present invention will be described with reference to experimental examples in order to help understanding the structure and effects of the present invention. However, the present invention is not limited by these experimental examples. The following experiments were performed under room temperature (25 ± 5 ° C.) and atmospheric pressure conditions, unless otherwise noted. Unless otherwise specified, "%" described below means "% by mass" and "part" means "part by mass".

The test samples used in the test are as follows. Sildenafil citrate is a compound that has a PDE5 inhibitory effect and is used as an active ingredient of a therapeutic agent for erectile dysfunction, and was used as a positive control in the following tests.
(1) Syldenafil: Syldenafil citrate (2) Amla extract: Extract obtained by removing the skin and seeds from the fruit, concentrating and drying and powdering (3) Black ginger extract: Extract of rhizome with hydrous ethanol and dried and powdered ( 4) Hihatsu extract: Extract of fruits extracted with hot water and dried and powdered (5) Black pepper extract: Extract of dried black pepper extracted with hydrous ethanol and powdered (6) Walnut extract: Seed coat with hydrous ethanol Extract and dry powdered extract (7) Mozuku extract: An extract of Okinawa mozuku extracted with citric acid, neutralized, concentrated and dried and powdered.

Experimental Example 1 Evaluation of PDE5 inhibitory effect (in vitro)
(1) Experimental method
Using the PDE5A assay kit (manufactured by BPS Bioscience Inc.), the PDE5 inhibition rate of each test sample was measured according to the following steps, and the PDE5 inhibitory effect was evaluated.
(A) 25 μL of diluted FAM-Cyclic-3', 5'-GMP was added to each well (Test, Blank, Substrate control, Positive control).
(B) Add 25 μL of PDE buffer to each well of “Blank”, and then each test sample solution (prepared to 300 μg / mL with 10% DMSO) (“Test” [test sample (2) to). (5)] wells and "Positive control" [test sample (1)] wells) or solvent (10% DMSO) ("Blank" and "Substrate control" wells) were added to each applicable well in an amount of 5 μL. did.
(C) Next, 20 μL of PDE assay buffer was added to each of the “Blank” and “Substrate control” wells. 20 μL of diluted PDE5A was added to the “Test” and “Positive control” wells (200 pg / reaction well).
(D) The reaction was carried out at 25 ° C. for 1 hour. The reaction was carried out by adding 100 μL of the diluted Binder to each well and shaking vigorously at 25 ° C. for 30 minutes.
(E) After the reaction, the fluorescence polarization of each well was measured with a plate reader (Excitation: 475-495 nm, Emission: 518-538 nm).
(F) The measured value (Blank value) of the well of "Blank" was subtracted from the measured value of each well (well of "Test", "Substrate control", "Positive control") to calculate the fluorescence polarization value. The PDE5 inhibition rate% of each test sample (Test: test sample (2) to (5), Positive control: test sample (1)) was calculated from the ratio with the fluorescence polarization value of "Substrate control".

(2) Experimental results The results are shown in Table 1.

As shown in Table 1, the PDE5 inhibition rate of sildenafil (100 nM), which is a positive control, was 89.6%. The PDE5 inhibition rate of Amla extract (Example 1) in this system was 59.2%. On the other hand, the inhibition rate of black ginger extract (Comparative Example 1) was 40.8%, the inhibition rate of Hihatsu extract (Comparative Example 2) was 8.2%, and the inhibition rate of black pepper extract (Comparative Example 3) was 0.3%. .. Among the comparative examples, black ginger extract is a plant containing 5,7-dimethoxyflavone, which is known to exhibit an inhibitory effect on phosphodiesterase activity (Non-Patent Document 5). It was confirmed that the inhibitory effect was significantly higher.
Thus, it was confirmed that the extract of Amla, a plant of the genus Phyllanthus, has a strong PDE5 inhibitory effect, although it is inferior to sildenafil.

Experimental Example 2 Evaluation of erection-inducing action (Part 1)
(1) Experimental method Rabbit (New Zealand White) was administered to the control group (SNP [1 mg / kg] only administration group: 2 animals) and the test sample administration group (SNP [1 mg / kg] + Amla extract [50 mg / kg / day]]. Divided into a total of 4 groups: SNP [1 mg / kg] + Amla extract [150 mg / kg / day] administration group, SNP [1 mg / kg] + Amla extract [500 mg / kg / day] administration group: 4 animals in each group) rice field. In the test sample administration group, Amla extract was orally administered continuously for 7 days, and then SNP (sodium nitroprusside), which is a NO donor, was intravenously administered once. On the final day of administration of Amla extract (7th day), Amla extract was orally ingested 60 minutes before SNP administration, and the penis was photographed before SNP administration and 30 minutes after SNP administration, and the length of the exposed penis was measured. In the control group, the penis was photographed before SNP administration and 30 minutes after SNP administration on the same day, and the length of the exposed penis was measured. The length (mm) of the exposed penis was measured by caliper to evaluate the effect of Amla extract on the erection-inducing effect of NO donors.

(2) Experimental results Figure 1 shows the results of measuring the length of the exposed penis. As shown in FIG. 1, Amla extract showed a dose-dependent effect of inducing penile erection. Penis before (left) and (right) SNP administration in the SNP [1 mg / kg] + Amla extract [500 mg / kg / day] administration group, which showed particularly remarkable effects among the test sample administration groups. The photographed image of the part is shown in FIG.

Experimental Example 3 Evaluation of erection-inducing action (Part 2)
(1) Experimental method Sildenafil [50 mg / kg / day] (Comparative Example 4) and walnuts were used in the same test as in Experimental Example 2 in place of Amla extract as a test sample to be orally administered using 3 rabbits in each group. It was carried out using an extract [500 mg / kg / day] (Comparative Example 5) and a mozuku extract [500 mg / kg / day] (Comparative Example 6). In addition, an experiment was also conducted on Amla extract [500 mg / kg / day] (Example 1) for oral administration. However, the length of the exposed penis was measured at 5 points before SNP administration on the final administration day (7th day) of Amla extract, and 30 minutes, 60 minutes, 90 minutes, and 120 minutes after SNP administration. On the final administration day, Amla extract was orally ingested 60 minutes before SNP administration.

(2) Experimental results The results are shown in FIG. As shown in FIG. 3, Comparative Example 5 (SNP [1 mg / kg] + walnut extract [500 mg / kg / day] administration) and Comparative Example 6 (SNP [1 mg / kg] + mozuku extract [500 mg / kg / day]] In all cases, the effect of inducing penile erection was lower than that in the control group (administering only SNP [1 mg / kg]). In Comparative Example 4 (SNP [1 mg / kg] + sildenafil [50 mg / kg / day] administration), the penile erection-inducing effect was sustained from SNP administration to 60 minutes, but was significantly reduced thereafter. On the other hand, in Example 1 (SNP [1 mg / kg] + Amla extract [500 mg / kg / day] administration), it was confirmed that the penile erection-inducing action was sustained from SNP administration to 90 minutes, and the penile erection was sustained for a long time. rice field. From the above, it was shown that Amla extract has an effect of enhancing high erectile function as compared with other plant extracts containing polyphenols.

Claims (5)

A composition for inhibiting the activity of phosphodiesterase 5 containing a processed product of a plant belonging to the genus Phyllanthus as an active ingredient. A composition for improving erectile function containing a processed product of a plant of the genus Phyllanthus as an active ingredient. At least one composition for improvement selected from the group consisting of benign prostatic hyperplasia symptoms, urinary function, livestock urinary function, and male vitality containing a processed product of a plant of the genus Phyllanthus as an active ingredient. The composition according to any one of claims 1 to 3, wherein the plant of the genus Phyllanthus is Amla. The composition according to any one of claims 1 to 4, wherein the composition is a food or drink composition, a pharmaceutical composition or a feed composition.

Images